Aclaris Therapeutics, Inc. (ACRS) Discusses Positive Interim Results From ATI-052 Phase 1a Trial and Potential Therapeutic Advantages Transcript
PresentationPlease note that today's conference is being recorded. I will now hand the conference over to your speaker host, Will Roberts, Head of Communications. Please go ahead.Good day and thank you for standing by. Welcome to the Aclaris ATI-052 Clinical Trial Update Conference Call. [Operator Instructions]William RobertsSenior VP of Corporate Communications & Investor Relations Thank you, Olivia, and good morning, everyone, and welcome to the Aclaris Therapeutics conference call to review the positive ...